IHF
iShares U.S. Healthcare Providers ETF
Set alert
59.94 USD -0.23 -0.38%
59.66 Day range 60.74
40.98 52-week range 60.90
- YTD
- +25.03%
- 1 year
- +23.16%
- Open
- 60.52
- Prev close
- 60.17
- Mkt cap
- 991.13M
- Vol
- 678.02K
- Avg vol
- 652.62K
- EPS
- 2.69
- P/E
- 22.30
- Div yield
- 0.00%
More statistics
- Low
- 59.66
- High
- 60.74
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 56.89
- 200-d avg
- 51.32
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 22.46
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 56.89
- 200-day average
- 51.32
About iShares U.S. Healthcare Providers ETF
The index measures the performance of the healthcare providers sector of the U.S. equity market, as defined by SPDJI. The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
News
- UnitedHealth Raises Guidance: What It Means for XLV and Other Healthcare ETFs
- Humana, UnitedHealth Stocks Pop After Medicare Surprise — ETFs In Focus
- Centene (CNC) Stock Slides After Medicare Advantage Update
- How Trump's Shutdown Standoff Could Hand Health-Care ETFs A Lifeline
- Jim Cramer On Centene's 40% Crash: Fewer ACA Signups, Sicker Patients, Pulled Guidance And Major Earnings Hit Trigger Selloff: 'This Is Horrifying'
- Trump's Tax Blitz Is An ETF Game-Changer—Are You Ready?
- Why Elevance Health Shares Are Surging Premarket On Wednesday?
- Health Insurance ETFs in Focus as RFK Jr Takes Over HHS
- US States Sue National Institutes Of Health Over $4 Billion Annual Cut In Biomedical Research Grant Budget
- Goldman Sachs Predicts Gradual Recovery For Tools And Contract Research Sector In 2025, Stable Large Pharma Spending Key To Recovery
Your note
Sign in to keep a note on IHF — it syncs with the Stock Master app.